{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:16:21Z","timestamp":1786997781898,"version":"build-2736575974"},"reference-count":28,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2010,5,1]],"date-time":"2010-05-01T00:00:00Z","timestamp":1272672000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Veterinary Journal"],"published-print":{"date-parts":[[2010,5]]},"DOI":"10.1016\/j.tvjl.2009.02.011","type":"journal-article","created":{"date-parts":[[2009,3,19]],"date-time":"2009-03-19T10:13:40Z","timestamp":1237457620000},"page":"236-240","source":"Crossref","is-referenced-by-count":10,"title":["Amylin reduces plasma glucagon concentration in cats"],"prefix":"10.1016","volume":"184","author":[{"given":"Daniela","family":"Furrer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Kaufmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia E.","family":"Reusch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A.","family":"Lutz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tvjl.2009.02.011_bib1","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1093\/ilar.47.3.186","article-title":"Animal models of type 2 diabetes: clinical presentation and pathophysiological relevance to the human condition","volume":"47","author":"Cefalu","year":"2006","journal-title":"Institute for Laboratory Animal Research Journal"},{"key":"10.1016\/j.tvjl.2009.02.011_bib2","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1016\/j.numecd.2008.01.012","article-title":"Guideline for management of postmeal glucose","volume":"18","author":"Ceriello","year":"2008","journal-title":"Nutrition, Metabolism and Cardiovascular Diseases"},{"key":"10.1016\/j.tvjl.2009.02.011_bib3","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1089\/15209150260007390","article-title":"Unresolved challenges with insulin therapy in type 1 and type 2 diabetes: potential benefit of replacing amylin, a second \u00df-cell hormone","volume":"4","author":"Edelman","year":"2002","journal-title":"Diabetes Technology and Therapeutics"},{"key":"10.1016\/j.tvjl.2009.02.011_bib4","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1055\/s-2002-34790","article-title":"The human amylin analog, pramlintide, reduces postprandial hyperglucagonemia in patients with type 2 diabetes mellitus","volume":"34","author":"Fineman","year":"2002","journal-title":"Hormone and Metabolic Research"},{"key":"10.1016\/j.tvjl.2009.02.011_bib5","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1093\/ilar.47.3.234","article-title":"Feline models of type 2 diabetes mellitus","volume":"47","author":"Henson","year":"2006","journal-title":"Institute for Laboratory Animal Research Journal"},{"key":"10.1016\/j.tvjl.2009.02.011_bib6","doi-asserted-by":"crossref","first-page":"784","DOI":"10.2337\/diacare.26.3.784","article-title":"Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patient with type 2 diabetes","volume":"26","author":"Hollander","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.tvjl.2009.02.011_bib7","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/oby.2004.76","article-title":"Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients","volume":"12","author":"Hollander","year":"2004","journal-title":"Obesity Research"},{"key":"10.1016\/j.tvjl.2009.02.011_bib8","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1056\/NEJM198908243210806","article-title":"Islet amyloid, islet-amyloid polypeptide and diabetes mellitus","volume":"321","author":"Johnson","year":"1989","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.tvjl.2009.02.011_bib9","first-page":"522","article-title":"Islet amyloid polypeptide: mechanisms of amyloidogenesis in the pancreatic islets and potential roles in diabetes mellitus","volume":"66","author":"Johnson","year":"1992","journal-title":"Laboratory Investigation"},{"key":"10.1016\/j.tvjl.2009.02.011_bib10","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/j.1939-1676.1999.tb02208.x","article-title":"Acute insulin response to intravenous arginine in non-obese healthy cats","volume":"13","author":"Kitamura","year":"1999","journal-title":"Journal of Veterinary Internal Medicine"},{"key":"10.1016\/j.tvjl.2009.02.011_bib11","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.2337\/diabetes.40.12.1615","article-title":"Decrease of stimulated amylin release precedes impairment of insulin secretion in type II diabetes","volume":"40","author":"Ludvik","year":"1991","journal-title":"Diabetes"},{"key":"10.1016\/j.tvjl.2009.02.011_bib12","doi-asserted-by":"crossref","first-page":"181","DOI":"10.2174\/1389450053174596","article-title":"The pancreatic hormone amylin as a centrally acting satiating hormone","volume":"6","author":"Lutz","year":"2005","journal-title":"Current Drug Targets"},{"key":"10.1016\/j.tvjl.2009.02.011_bib13","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0195-5616(95)50051-8","article-title":"Pathogenesis of feline diabetes mellitus","volume":"25","author":"Lutz","year":"1995","journal-title":"Veterinary Clinics of North America Small Animal Practice"},{"key":"10.1016\/j.tvjl.2009.02.011_bib14","first-page":"27","article-title":"Plasma amylin and insulin concentrations in normoglycemic and hyperglycaemic cats","volume":"37","author":"Lutz","year":"1996","journal-title":"Canadian Veterinary Journal"},{"key":"10.1016\/j.tvjl.2009.02.011_bib15","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/dmrr.419","article-title":"Pramlintide reduces postprandial glucose excursion when added to insulin lispro in subjects with type 2 diabetes: a dose-timing study","volume":"20","author":"Maggs","year":"2004","journal-title":"Diabetes\/Metabolism Research and Reviews"},{"key":"10.1016\/j.tvjl.2009.02.011_bib16","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.2337\/diabetes.40.12.1701","article-title":"Islet amyloid polypeptide and insulin secretion from isolated perfused pancreas of fed, fasted, glucose-treated and dexamethasone-treated rats","volume":"40","author":"O\u2019Brien","year":"1991","journal-title":"Diabetes"},{"key":"10.1016\/j.tvjl.2009.02.011_bib17","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1089\/15209150252924094","article-title":"Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes","volume":"4","author":"Ratner","year":"2002","journal-title":"Diabetes Technology and Therapeutics"},{"key":"10.1016\/j.tvjl.2009.02.011_bib18","doi-asserted-by":"crossref","first-page":"368","DOI":"10.3109\/00016925309136722","article-title":"Catheter replacement of the needle in percutaneous arteriography","volume":"39","author":"Seldinger","year":"1953","journal-title":"Acta Radiologica"},{"key":"10.1016\/j.tvjl.2009.02.011_bib19","doi-asserted-by":"crossref","first-page":"987","DOI":"10.2337\/diacare.21.6.987","article-title":"Pramlintide, a synthetic analog of human amylin, improves the metabolic profile of patients with type 2 diabetes using insulin","volume":"21","author":"Thompson","year":"1998","journal-title":"Diabetes Care"},{"key":"10.1016\/j.tvjl.2009.02.011_bib20","first-page":"725","article-title":"Intravenous arginine stimulation test in cats with transient and non-transient diabetes mellitus","volume":"20","author":"Tschuor","year":"2006","journal-title":"Journal of Veterinary Internal Medicine"},{"key":"10.1016\/j.tvjl.2009.02.011_bib21","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1046\/j.1365-2982.2002.00311.x","article-title":"Effects of pramlintide, an amylin analogue, on gastric emptying in type 1 and 2 diabetes mellitus","volume":"14","author":"Vella","year":"2002","journal-title":"Neurogastroenterology and Motility"},{"key":"10.1016\/j.tvjl.2009.02.011_bib22","doi-asserted-by":"crossref","first-page":"5036","DOI":"10.1073\/pnas.87.13.5036","article-title":"Islet amyloid polypeptide: pinpointing amino acid residues linked to amyloid fibril formation","volume":"87","author":"Westermark","year":"1990","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.tvjl.2009.02.011_bib23","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.2174\/1381612013397357","article-title":"Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: a physiological approach toward improved metabolic control","volume":"7","author":"Weyer","year":"2001","journal-title":"Current Pharmaceutical Design"},{"key":"10.1016\/j.tvjl.2009.02.011_bib24","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S1054-3589(05)52002-7","article-title":"Tissue expression and secretion of amylin. Amylin: physiology and pharmacology","volume":"52","author":"Young","year":"2005","journal-title":"Advances in Pharmacology"},{"key":"10.1016\/j.tvjl.2009.02.011_bib25","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S1054-3589(05)52009-X","article-title":"Inhibition of insulin secretion. Amylin: physiology and pharmacology","volume":"52","author":"Young","year":"2005","journal-title":"Advances in Pharmacology"},{"key":"10.1016\/j.tvjl.2009.02.011_bib26","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S1054-3589(05)52018-0","article-title":"Clinical studies. Amylin: physiology and pharmacology","volume":"52","author":"Young","year":"2005","journal-title":"Advances in Pharmacology"},{"key":"10.1016\/j.tvjl.2009.02.011_bib27","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/(SICI)1098-2299(199604)37:4<231::AID-DDR5>3.0.CO;2-M","article-title":"Preclinical pharmacology of pramlintide in the rat: comparison with human and rat amylin","volume":"37","author":"Young","year":"1996","journal-title":"Drug Development Research"},{"key":"10.1016\/j.tvjl.2009.02.011_bib28","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1007\/s00125-008-1201-y","article-title":"Hyperglycemia but not hyperlipidemia causes beta cell dysfunction and beta cell loss in the domestic cat","volume":"52","author":"Zini","year":"2009","journal-title":"Diabetologia"}],"container-title":["The Veterinary Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1090023309000653?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1090023309000653?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,20]],"date-time":"2018-12-20T20:28:46Z","timestamp":1545337726000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1090023309000653"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,5]]}},"alternative-id":["S1090023309000653"],"URL":"https:\/\/doi.org\/10.1016\/j.tvjl.2009.02.011","relation":{},"ISSN":["1090-0233"],"issn-type":[{"value":"1090-0233","type":"print"}],"subject":[],"published":{"date-parts":[[2010,5]]}}}